Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
29.4
USD
|
+1.84%
|
|
-1.84%
|
-8.98%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,057
|
2,493
|
3,268
|
1,892
|
1,670
|
-
|
-
|
Enterprise Value (EV)
1 |
2,022
|
2,449
|
3,214
|
1,759
|
1,378
|
1,146
|
863.5
|
P/E ratio
|
-14.6
x
|
73.5
x
|
18.6
x
|
15.2
x
|
13.2
x
|
7.54
x
|
5.74
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.9
x
|
8.16
x
|
7.46
x
|
3.25
x
|
2.35
x
|
1.99
x
|
1.69
x
|
EV / Revenue
|
12.7
x
|
8.02
x
|
7.34
x
|
3.02
x
|
1.94
x
|
1.36
x
|
0.87
x
|
EV / EBITDA
|
74.2
x
|
23
x
|
22.4
x
|
8.13
x
|
7.92
x
|
3.51
x
|
2.25
x
|
EV / FCF
|
-677
x
|
24.9
x
|
22.3
x
|
8.03
x
|
10.7
x
|
4.76
x
|
2.54
x
|
FCF Yield
|
-0.15%
|
4.01%
|
4.49%
|
12.5%
|
9.32%
|
21%
|
39.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,889
|
58,472
|
59,318
|
58,572
|
56,792
|
-
|
-
|
Reference price
2 |
36.15
|
42.64
|
55.10
|
32.30
|
29.40
|
29.40
|
29.40
|
Announcement Date
|
3/25/21
|
2/28/22
|
2/21/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
159.7
|
305.4
|
437.9
|
582
|
709.8
|
839.3
|
990.2
|
EBITDA
1 |
27.26
|
106.4
|
143.6
|
216.4
|
174
|
326.8
|
384.6
|
EBIT
1 |
16.99
|
87.53
|
120.2
|
192
|
184.3
|
308.1
|
396.6
|
Operating Margin
|
10.63%
|
28.66%
|
27.45%
|
32.99%
|
25.96%
|
36.71%
|
40.05%
|
Earnings before Tax (EBT)
1 |
-36.94
|
37.43
|
104.7
|
173.4
|
163.7
|
303.2
|
397.4
|
Net income
1 |
-63.85
|
34.6
|
181.5
|
128.9
|
136.3
|
236.5
|
302.3
|
Net margin
|
-39.97%
|
11.33%
|
41.44%
|
22.14%
|
19.2%
|
28.18%
|
30.52%
|
EPS
2 |
-2.480
|
0.5800
|
2.970
|
2.130
|
2.226
|
3.897
|
5.118
|
Free Cash Flow
1 |
-2.987
|
98.26
|
144.3
|
219.1
|
128.4
|
240.7
|
340.5
|
FCF margin
|
-1.87%
|
32.17%
|
32.95%
|
37.64%
|
18.09%
|
28.68%
|
34.38%
|
FCF Conversion (EBITDA)
|
-
|
92.38%
|
100.5%
|
101.24%
|
73.79%
|
73.65%
|
88.53%
|
FCF Conversion (Net income)
|
-
|
284.01%
|
79.51%
|
170.02%
|
94.23%
|
101.78%
|
112.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
2/28/22
|
2/21/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
91.21
|
85.31
|
107
|
117.2
|
128.3
|
119.1
|
134.2
|
160.3
|
168.4
|
154.6
|
173.9
|
185.5
|
196.6
|
180
|
205.4
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
52.97
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
28.63
|
27.56
|
33.12
|
11.9
|
47.61
|
40.42
|
46.9
|
64.51
|
40.2
|
52.03
|
3.184
|
55.62
|
56.21
|
57.81
|
74.31
|
Operating Margin
|
31.39%
|
32.3%
|
30.94%
|
10.15%
|
37.11%
|
33.93%
|
34.95%
|
40.25%
|
23.87%
|
33.65%
|
1.83%
|
29.99%
|
28.59%
|
32.11%
|
36.18%
|
Earnings before Tax (EBT)
1 |
24.48
|
23.38
|
29.23
|
7.967
|
44.1
|
37.78
|
44.1
|
51.83
|
39.69
|
51.78
|
2.025
|
51.21
|
50.39
|
55.75
|
72.31
|
Net income
1 |
22.71
|
21.48
|
23.53
|
87.79
|
48.51
|
29.48
|
34.3
|
38.47
|
26.61
|
38.33
|
1.162
|
38.64
|
38.14
|
42.55
|
55.24
|
Net margin
|
24.9%
|
25.18%
|
21.99%
|
74.91%
|
37.81%
|
24.75%
|
25.56%
|
24%
|
15.8%
|
24.79%
|
0.67%
|
20.84%
|
19.4%
|
23.63%
|
26.9%
|
EPS
2 |
0.3800
|
0.3500
|
0.3900
|
1.440
|
0.7900
|
0.4800
|
0.5600
|
0.6300
|
0.4500
|
0.6700
|
0.0133
|
0.7083
|
0.7200
|
0.6850
|
0.8750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/21/23
|
5/2/23
|
8/1/23
|
10/31/23
|
2/22/24
|
4/30/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
34.4
|
44.3
|
54.1
|
133
|
292
|
524
|
806
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.99
|
98.3
|
144
|
219
|
128
|
241
|
340
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
29.6%
|
37.7%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
3.630
|
3.720
|
4.650
|
-
|
Capex
1 |
0
|
0.3
|
0.17
|
0.31
|
0.97
|
0.41
|
1.59
|
Capex / Sales
|
0%
|
0.1%
|
0.04%
|
0.05%
|
0.14%
|
0.05%
|
0.16%
|
Announcement Date
|
3/25/21
|
2/28/22
|
2/21/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
29.4
USD Average target price
43
USD Spread / Average Target +46.26% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.98% | 1.67B | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|